240 related articles for article (PubMed ID: 16289028)
1. Attenuation of morphine withdrawal signs by intracerebral administration of 18-methoxycoronaridine.
Panchal V; Taraschenko OD; Maisonneuve IM; Glick SD
Eur J Pharmacol; 2005 Nov; 525(1-3):98-104. PubMed ID: 16289028
[TBL] [Abstract][Full Text] [Related]
2. 18-MC acts in the medial habenula and interpeduncular nucleus to attenuate dopamine sensitization to morphine in the nucleus accumbens.
Taraschenko OD; Shulan JM; Maisonneuve IM; Glick SD
Synapse; 2007 Jul; 61(7):547-60. PubMed ID: 17447255
[TBL] [Abstract][Full Text] [Related]
3. 18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats.
Glick SD; Ramirez RL; Livi JM; Maisonneuve IM
Eur J Pharmacol; 2006 May; 537(1-3):94-8. PubMed ID: 16626688
[TBL] [Abstract][Full Text] [Related]
4. Is antagonism of alpha3beta4 nicotinic receptors a strategy to reduce morphine dependence?
Taraschenko OD; Panchal V; Maisonneuve IM; Glick SD
Eur J Pharmacol; 2005 Apr; 513(3):207-18. PubMed ID: 15862802
[TBL] [Abstract][Full Text] [Related]
5. Antagonism of orexin type 1 receptors in the locus coeruleus attenuates signs of naloxone-precipitated morphine withdrawal in rats.
Azizi H; Mirnajafi-Zadeh J; Rohampour K; Semnanian S
Neurosci Lett; 2010 Oct; 482(3):255-9. PubMed ID: 20667500
[TBL] [Abstract][Full Text] [Related]
6. Brain regions mediating alpha3beta4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration.
Glick SD; Sell EM; Maisonneuve IM
Eur J Pharmacol; 2008 Dec; 599(1-3):91-5. PubMed ID: 18930043
[TBL] [Abstract][Full Text] [Related]
7. Elevated mu-opioid receptor expression in the nucleus of the solitary tract accompanies attenuated withdrawal signs after chronic low dose naltrexone in opiate-dependent rats.
Van Bockstaele EJ; Rudoy C; Mannelli P; Oropeza V; Qian Y
J Neurosci Res; 2006 Feb; 83(3):508-14. PubMed ID: 16385558
[TBL] [Abstract][Full Text] [Related]
8. Brain regions mediating α3β4 nicotinic antagonist effects of 18-MC on nicotine self-administration.
Glick SD; Sell EM; McCallum SE; Maisonneuve IM
Eur J Pharmacol; 2011 Nov; 669(1-3):71-5. PubMed ID: 21871879
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of morphine withdrawal by the NMDA receptor antagonist MK-801 in rat is age-dependent.
Zhu H; Barr GA
Synapse; 2001 Jun; 40(4):282-93. PubMed ID: 11309844
[TBL] [Abstract][Full Text] [Related]
10. Chronic very low dose naltrexone administration attenuates opioid withdrawal expression.
Mannelli P; Gottheil E; Peoples JF; Oropeza VC; Van Bockstaele EJ
Biol Psychiatry; 2004 Aug; 56(4):261-8. PubMed ID: 15312814
[TBL] [Abstract][Full Text] [Related]
11. Mirtazapine, a noradrenergic and specific serotonergic antidepressant, attenuates morphine dependence and withdrawal in Sprague-Dawley rats.
Kang L; Wang D; Li B; Hu M; Zhang P; Li J
Am J Drug Alcohol Abuse; 2008; 34(5):541-52. PubMed ID: 18618337
[TBL] [Abstract][Full Text] [Related]
12. Injections of an opioid antagonist into the locus coeruleus and periaqueductal gray but not the amygdala precipitates morphine withdrawal in the 7-day-old rat.
Jones KL; Barr GA
Synapse; 2001 Feb; 39(2):139-51. PubMed ID: 11180501
[TBL] [Abstract][Full Text] [Related]
13. The selective mGlu2/3 receptor antagonist LY341495 exacerbates behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons.
Rasmussen K; Hsu MA; Vandergriff J
Neuropharmacology; 2004 Apr; 46(5):620-8. PubMed ID: 14996539
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of nitric oxide synthase and the opioid withdrawal syndrome.
London ED; Kimes AS; Vaupel DB
NIDA Res Monogr; 1995; 147():170-81. PubMed ID: 8742786
[TBL] [Abstract][Full Text] [Related]
15. Role of different brain structures in the expression of the physical morphine withdrawal syndrome.
Maldonado R; Stinus L; Gold LH; Koob GF
J Pharmacol Exp Ther; 1992 May; 261(2):669-77. PubMed ID: 1578378
[TBL] [Abstract][Full Text] [Related]
16. [A method for the quantitative assessment of the withdrawal syndrome in morphine-dependent rats].
Sudakov SK; Borisova EV; Rusakov DIu
Eksp Klin Farmakol; 1994; 57(2):60-3. PubMed ID: 8205055
[TBL] [Abstract][Full Text] [Related]
17. Effects of 18-methoxycoronaridine on acute signs of morphine withdrawal in rats.
Rho B; Glick SD
Neuroreport; 1998 May; 9(7):1283-5. PubMed ID: 9631413
[TBL] [Abstract][Full Text] [Related]
18. Increased release of excitatory amino acids in rat locus coeruleus in kappa-opioid agonist dependent rats precipitated by nor-binaltorphimine.
Hoshi K; Ma T; Oh S; Ho IK
Brain Res; 1997 Apr; 753(1):63-8. PubMed ID: 9125432
[TBL] [Abstract][Full Text] [Related]
19. Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor.
Glick SD; Rossman K; Rao NC; Maisonneuve IM; Carlson JN
Neuropharmacology; 1992 May; 31(5):497-500. PubMed ID: 1528400
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of antiaddictive actions of ibogaine.
Glick SD; Maisonneuve IS
Ann N Y Acad Sci; 1998 May; 844():214-26. PubMed ID: 9668680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
